Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythromycin for inflammatory mediators in chronic rhinosinusitis
2008-005828-84Phase 4Completed
- Sponsor
- Royal National Throat, Nose and Ear Hospital
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of erythromycin in chronic rhinosinusitis (CRS) and rhinosinusitis, sponsored by Royal National Throat, Nose and Ear Hospital. Primary endpoints: Change in eosinophilic protein cationic concentration and Change in myeloperoxidase concentration. Started Jan 2009; status: completed.
02
Drugs
erythromycin
03
Conditions
chronic rhinosinusitis (CRS)rhinosinusitis
Beyond the preview
Go deeper on 2008-005828-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005828-84.